NEWTOWN, Pa., March 05, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS),

PharmaMar (MCE: PHM) has announced today the signing of a commercialization and distribution license agreement with Pint Pharma International, S.A. for the marine-derived anticancer drug Aplidin® (plitidepsin) in Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Mexico, Paraguay, Peru, Uruguay and Venezuela.


Pint Pharma has its own pharmacovigilance system that monitors the safety and efficacy of our products when our customers are using them.

If a side effect is experienced, please write an email to: